X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Andrew Powaleny

Andrew Powaleny is Senior Director of Public Affairs at PhRMA and leads the organization's scientific communications. Before joining PhRMA in 2015, he worked in public affairs for a small firm in Washington, DC and served as Deputy Press Secretary for the House Committee on Energy and Commerce. Andrew came to Washington, D.C. via Connecticut with a degree from Eastern Connecticut State University where he majored in public policy and government. Andrew is active as a runner and volunteer with the DC Front Runners; most recently serving on its Board of Directors for three years as co-race director. He is also a member of the NLGJA: The Association of LGBTQ Journalists and mentors students through his alumni association with The Fund for American Studies. Andrew is passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.

Recent Posts

Recognizing Hepatitis R&D on World Hepatitis Day

By Andrew Powaleny  |    July 28, 2021
Hepatitis is an inflammation of the liver, most commonly caused by a viral infection. There are five main hepatitis viruses, with types A, B, C most common. In 2018, the Centers for Disease...   Read More

Watch: Building trust and enhancing clinical trial diversity

By Andrew Powaleny  |    June 24, 2021
On June 22, during The Atlantic’s Health Equity Summit, PhRMA hosted a conversation on clinical trial diversity. PhRMA Chief Operating Officer Lori Reilly and Genentech Vice President and Chief...   Read More

More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities

By Andrew Powaleny  |    June 22, 2021
We are in a new era of medicine where groundbreaking biopharmaceutical research and development is transforming medicine, but these innovations are meaningless if they don’t reach patients,...   Read More

Researchers to shine light on biopharmaceutical R&D with policymakers

By Andrew Powaleny  |    June 15, 2021
Today, biopharmaceutical researchers from PhRMA member companies are meeting virtually with members of Congress and staff to share their stories of transforming game-changing scientific...   Read More

ICYMI: PhRMA president and CEO Stephen J. Ubl joins other industry leaders for a conversation on COVID-19 vaccines with Axios

By Andrew Powaleny  |    May 21, 2021
On May 19, Axios hosted an event discussing the unprecedented development of COVID-19 vaccines and the road ahead. Speakers included NIAID Director Dr. Anthony Fauci, Pfizer Chairman & CEO Dr....   Read More

How strengthening the biosimilar marketplace benefits patients

By Andrew Powaleny  |    May 18, 2021
Biologics are medicines that are made from living organisms through highly complex manufacturing processes and include a wide variety of medicines such as therapeutic proteins, monoclonal...   Read More

Reflecting on Mental Health Awareness Month

By Andrew Powaleny  |    May 4, 2021
As communities around the world continue to grapple with the impact of COVID-19, the importance of furthering our understanding of the impact on our mental health is undeniable.   Read More

New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections, but future pipeline remains challenging

By Andrew Powaleny  |    April 29, 2021
The discovery and introduction of antibiotics in the 1940s transformed modern medicine and enabled tremendous progress in health care and life expectancy. Today, this progress is being threatened...   Read More

ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures

By Andrew Powaleny  |    April 12, 2021
America’s biopharmaceutical companies are at the heart of a research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. The ongoing...   Read More

ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines

By Andrew Powaleny  |    March 8, 2021
Building on deep scientific knowledge gained from decades of experience with viruses such as MERS, SARS, influenza, HIV and Hepatitis C, biopharmaceutical companies have made unprecedented progress   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates